Professor Goldsteins research contributions include: Co-discovery and isolation of the thymosin family of peptides in the 1960s First clinical trials of thymosin preparations in immunodeficient children (1974) Characterization of thymosin beta-4s actin-binding and wound healing properties Development of therapeutic applications for tissue repair and regeneration Over 450 published scientific articles and 25+ patents related to thymosins Leadership in translating thymosin research toward clinical development Disclaimer: This spotlight is provided for educational purposes to acknowledge scientific contributions to BPC-157 and TB-500/thymosin beta-4 research
Research spanning over 40 years demonstrates GHK-Cu affects more than 31% of human genes, with documented benefits including a 70% increase in collagen production, 30-50% faster wound healing, and hair growth comparable to 5% minoxidil
44 Orforglipron In a phase 2, randomized, double-blind trial, daily oral orforglipron (12, 24, 36, or 45 mg) for 36 weeks led to weight reductions of 9.414.7% in adults with pre-obesity or obesity (without diabetes), compared to 2.3% with placebo, and showed no signs of plateau (Table 2)
SNAC temporarily protected semaglutide from degradation and enhanced transcellular absorption
A pharmacy operating under USP 797 Category 3 conditions with validated stability data can assign longer BUDs
